Dishman Carbogen Amcis

What Dishman Carbogen Amcis does

Dishman Carbogen Amcis Ltd is a publicly listed (BSE smallcap, NSE: DCAL) global pharmaceutical outsourcing partner headquartered in Ahmedabad, Gujarat, India, with operational roots reaching back to 1995 and approximately 1,001–5,000 employees. The company serves global pharmaceutical manufacturers through Contract Research and Manufacturing Services (CRAMS), spanning clinical and commercial API development, scale-up, manufacturing of Highly Potent APIs (HiPoAPI) requiring contained handling, analytical testing, life cycle management, and finished dosage formulation including soft gel capsules. Product offerings also include niche APIs, vitamin D analogues, quaternary salts, and health and personal care actives, with enabling services for quality and regulatory affairs.

Underlying operations run across 10 manufacturing and development sites in six countries — India (Ahmedabad, Naroda, Bavla), Switzerland (Neuland), the United Kingdom, France, the Netherlands, and China (Shanghai) — supported by approximately 100 metric tons of API manufacturing scale and 1,150 m3 of reactor capacity. The company maintains a heavy regulatory infrastructure footprint with USFDA-cleared India facilities, EDQM CEP, PMDA (Japan), NMPA (China), and EUDRA GMP (Italian Medicines Agency) certifications, which together act as a gating requirement for serving large global pharma customers. A 2021 clinical research partnership with Boston University School of Medicine on Calcifediol (vitamin D3) extended the vitamin D analogues portfolio into adjacent therapeutic applications.

The company monetizes through negotiated, project-based B2B contracts across three revenue streams: CRAMS & HiPoAPI manufacturing services, pharmaceutical product sales (niche APIs, vitamin D analogues, quaternary salts, health and personal care actives), and finished dosage supply. Pricing is not publicly disclosed; go-to-market is direct enterprise field sales to pharmaceutical company buyers, with revenue scaled on long-term supply and development agreements. Customer engagement is anchored by multi-jurisdiction regulatory compliance, specialized containment capabilities for high-potency compounds, and proximity to clients across Europe, Asia, and North America.

Name

Dishman Carbogen Amcis

Legal name

Dishman Carbogen Amcis Ltd

Website

https://dishmangroup.com

Company type

Public

Founded year

1995

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Dishman Carbogen Amcis Ltd is a global pharmaceutical outsourcing partner offering CRAMS, Highly Potent API manufacturing, and finished dosage services. It serves global pharmaceutical manufacturers from 10 sites across India, Switzerland, the UK, France, the Netherlands, and China.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Small-Molecule API & Intermediates CDMO (HLAGABAA)

akta.pro secondary industries

Small-Molecule API Commercial Manufacturing (HLAGAHAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Pharmaceutical contract manufacturing
• API development services
• Highly potent APIs
• Finished dosage manufacturing
• Pharmaceutical CRAMS services

Headquarters

HQ city

Ahmedabad

HQ country

India

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

1. CRAMS & HiPoAPI Manufacturing Services: Contract research and manufacturing services providing development, scale-up, and commercial manufacturing of active pharmaceutical ingredients (APIs) and highly potent APIs for pharmaceutical companies. Revenue is generated through long-term B2B contracts with pharmaceutical clients.
2. Pharmaceutical Products: Sale of niche APIs, vitamin D analogues, quaternary salts, and health and personal care solutions to pharmaceutical manufacturers. Revenue from product sales across multiple therapeutic and industrial applications.
3. Finished Dosages: Manufacturing and supply of finished dosage forms including soft gel capsules and formulation products for pharmaceutical clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Dishman Carbogen Amcis is a global pharmaceutical outsourcing partner providing contract research and manufacturing services (CRAMS) and highly potent active pharmaceutical ingredients (HiPoAPI) to pharmaceutical companies. The company offers end-to-end services spanning clinical API development, scale-up, commercial manufacturing, analytical testing, life cycle management, and finished dosage forms (including soft gel capsules and vitamin D analogues), operating 10 manufacturing sites across 6 countries with 100 metric tons of API manufacturing scale and 1,150 m3 of reactor capacity.

Product overview

Dishman Carbogen Amcis is a global pharmaceutical outsourcing partner offering a comprehensive portfolio of products and services. The core offering includes CRAMS & HiPoAPI services (Contract Research and Manufacturing Services, Highly Potent Active Pharmaceutical Ingredients) encompassing development services, manufacturing services, highly potent API supply, analytical capabilities, life cycle management, and finished dosages. The product portfolio also includes health and personal care solutions, vitamin D analogues and soft gel capsules, niche APIs for pharmaceutical industries, and quaternary salts. Enabling services include quality and regulatory affairs support. The company operates across 10 sites in India, Switzerland, UK, France, Netherlands, and China with 30 years of clinical API development experience, 100 metric tons scale manufacturing capacity for API production, and 1150 m3 of API production capacity.

Differentiator

Problem solved

Functional benefit

Products and services

• CRAMS & HiPoAPI (Contract Research and Manufacturing Services, Highly Potent Active Pharmaceutical Ingredients) Comprehensive contract research and manufacturing services for pharmaceutical companies, including API development, scale-up, commercial manufacturing, highly potent API supply, analytical testing, life cycle management, and finished dosage forms. Targeted at global pharmaceutical manufacturers requiring outsourced development and manufacturing capabilities.
• Health and Personal Care Solutions Active pharmaceutical ingredients for disinfectant and cosmetics applications, sold to pharmaceutical and personal care manufacturers as bulk APIs.
• Vitamin D Analogues and Soft Gel Capsules Niche vitamin D analogue APIs and soft gel capsule formulations supplied to pharmaceutical companies for therapeutic applications including vitamin D deficiency and immunity-related treatments.
• Niche APIs for Pharmaceutical Industries Niche active pharmaceutical ingredients supplied for specialized pharmaceutical development, supporting drug developers requiring less common API compounds.
• Quaternary Salts Quaternary ammonium salt compounds supplied for use as pharmaceutical ingredients and intermediates.

Quantifiable outcome

• 300 metric tons of disinfectant APIs manufactured and exported to fight COVID-19 since March 2020

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered core.

• IWB (Industrielle Werke Basel) and its subsidiary PlanecocoreStrategic or Co-development Partner · 30 June 2026CARBOGEN AMCIS AG, the wholly-owned Swiss subsidiary of Dishman Carbogen Amcis, partnered with IWB (Industrielle Werke Basel) and its subsidiary Planeco to commission a 1,200 kWp ground-mounted photovoltaic system at the Neuland site in Switzerland. The system comprises 2,448 solar modules across approximately 6,200 square meters and is described as one of the most efficient conventional ground-mounted solar systems in the Swiss Mittelland region. This represents a targeted investment toward meeting the company's environmental sustainability goals.
• Boston University School of MedicinecoreStrategic or Co-development Partner · 9 December 2021Dishman Carbogen Amcis partnered with Boston University School of Medicine on a clinical research study that demonstrated oral 25-Hydroxyvitamin D3 (Calcifediol) was able to correct vitamin D deficiency/insufficiency in patients with COVID-19 and resulted in improved immune function by increasing blood markers. The study showed positive clinical outcomes, which aligns with the company's vitamin D analogues product portfolio.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Regional players

• Syngene International: India-based contract research and manufacturing services organization offering drug discovery, development, and small-molecule manufacturing. Broader discovery/CRO scope than DCAL but overlapping in API manufacturing and pharma services.

Direct peers

• Neuland Laboratories: India-based API and CDMO company with USFDA, EMA, and PMDA approvals. Comparable niche API focus and CRAMS offering, with similar customer overlap in innovator pharma.
• Laurus Labs: India-based CDMO specializing in APIs, intermediates, and formulation services. Direct competitor in generic API manufacturing and CRAMS with comparable regulatory footprint and target customers.
• Sai Life Sciences: India-based CRAMS provider offering API development, HPAPI, and formulation services. Privately held but directly competes with DCAL in small-molecule CRAMS contracts from global pharma.
• Piramal Pharma Solutions: Piramal's CDMO arm offers integrated API, HPAPI, and finished dosage services globally. Direct peer in CRAMS scope, with broader biologics and ADC capabilities; competes for similar innovator pharma contracts.
• Divi's Laboratories: India-headquartered, large-cap API manufacturer with strong CRAMS/HPAPI capabilities and USFDA/EMA inspections across multiple sites. Closest direct peer to DCAL in scale, business model, and customer base (global generic and innovator pharma).
• Hikal Ltd: Indian CDMO focused on APIs, intermediates, and contract manufacturing for pharma and agrochemical customers. Comparable scale and direct competitor in small-molecule CRAMS.
• Jubilant Pharmova: Indian CDMO with API manufacturing, CRAMS, and dosage form capabilities across multiple geographies. Similar business model and end-market exposure to DCAL.

Broad incumbents

• Lonza Group: Swiss-headquartered global CDMO leader offering APIs, HPAPIs, and biologics manufacturing at scale. CARBOGEN AMCIS (DCAL's Swiss subsidiary) competes with Lonza in HPAPI niche; serves overlapping innovator pharma customers.

Others

• Cambrex (Eurofins Discovery): Now part of Eurofins, Cambrex historically was a leading small-molecule API and HPAPI CDMO with USFDA-inspected facilities. Competes with DCAL/CARBOGEN AMCIS for innovator pharma API contracts; broader European footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dishman-carbogen-amcis-limited

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dishman Carbogen Amcis